Feature Channels: Pharmaceuticals

Filters close
access_time Embargo lifts in 2 days
This news release is embargoed until 18-Sep-2024 5:00 PM EDT Released to reporters: 13-Sep-2024 10:05 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 18-Sep-2024 5:00 PM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Newswise: Decoding atractylodes lancea: a genomic journey through adaptation and metabolism
Released: 11-Sep-2024 11:05 AM EDT
Decoding atractylodes lancea: a genomic journey through adaptation and metabolism
Chinese Academy of Sciences

Scientists have decoded the genetic blueprint of Atractylodes lancea, a prized herb in traditional Chinese medicine. Through comprehensive genome resequencing, the study unveils how natural variations drive the plant's evolution and metabolic adaptations, particularly affecting the production of key medicinal compounds.

Released: 11-Sep-2024 8:05 AM EDT
Varda Announces Collaboration with SSPC to Improve Fundamental Understanding of Microgravity Crystallization
Varda Space Industries Inc.

Varda Space Industries, Inc., the world's first in-space pharmaceutical processing and hypersonic Earth re-entry logistics company, together with SSPC, the Research Ireland Centre for Pharmaceuticals, today announced a research collaboration that aims to advance mathematical modeling of crystallization in microgravity, the first such framework that considers polymorphism.

   
Released: 5-Sep-2024 12:05 PM EDT
Risky Combos of Psychiatric Drugs Prescribed for Young Patients
Rutgers University-New Brunswick

Rutgers Health researchers and others find hundreds of young patients receive potentially dangerous medication combinations, raising concerns about prescription practices.

Newswise: Adding anti-clotting drugs to stroke care ineffective, clinical trial finds
4-Sep-2024 8:00 AM EDT
Adding anti-clotting drugs to stroke care ineffective, clinical trial finds
Washington University in St. Louis

Opeolu Adeoye, MD a professor of emergency medicine at Washington University School of Medicine in St. Louis, led a national clinical trial that found that two anti-coagulant medications are ineffective at improving post-treatment outcomes for stroke patients.

Not for public release

This news release is embargoed until 3-Sep-2024 11:00 AM EDT Released to reporters: 29-Aug-2024 11:00 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 3-Sep-2024 11:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Newswise: Pharmacy professor receives $1.9M award to tackle gene therapy challenges
Released: 3-Sep-2024 9:05 AM EDT
Pharmacy professor receives $1.9M award to tackle gene therapy challenges
Binghamton University, State University of New York

Assistant Professor of Pharmaceutical Sciences Kuo-Ching (KC) Mei from Binghamton University, State University of New York and his team have won the $1.9M Maximizing Investigators’ Research Award (MIRA) for Early Stage Investigators (ESI) from the National Institute of General Medical Sciences to tackle gene therapy challenges.

   

Not for public release

This news release is embargoed until 2-Sep-2024 5:00 PM EDT Released to reporters: 27-Aug-2024 2:00 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 2-Sep-2024 5:00 PM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Newswise: Synchronous removal of Cr(VI) and antibiotics using a novel photocatalyst
Released: 31-Aug-2024 6:05 AM EDT
Synchronous removal of Cr(VI) and antibiotics using a novel photocatalyst
Chinese Academy of Sciences

In a landmark development for environmental conservation, a pioneering plasmonic photocatalyst has been engineered to synergistically degrade the potent pollutants hexavalent chromium (Cr(VI)) and norfloxacin from aquatic environments.

   
Released: 30-Aug-2024 8:05 AM EDT
Novel chemical tool aims to streamline drug-making process
Ohio State University

The invention of a tool capable of unlocking previously impossible organic chemical reactions has opened new pathways in the pharmaceutical industry to create effective drugs more quickly.

Newswise: Nutrition know-how for patients taking anti-obesity medication
Released: 29-Aug-2024 1:05 PM EDT
Nutrition know-how for patients taking anti-obesity medication
UT Southwestern Medical Center

Since anti-obesity medications have become more widely known and prescribed, they have been touted as game-changing treatments for chronic overweight and obesity. But one common misconception about these medications is that they’re a magic bullet for better health, and it doesn’t necessarily matter what you eat when you’re taking them.

Released: 29-Aug-2024 10:05 AM EDT
How You Can Practice Pharmaceutical Safety
Tufts University

When you pick up a prescription or get a vaccination, it’s paramount that you trust the medication is safe. In the U.S., a system of laws, procedures, and personal responsibility combine to ensure drug safety, or pharmacovigilance.

Released: 29-Aug-2024 6:05 AM EDT
EVOQ Therapeutics Secures $2 Million in Funding for Advanced Autoimmune NanoDisc Therapies
EVOQ Therapeutics, Inc.

EVOQ Therapeutics, Inc. (EVOQ) a biopharmaceutical company dedicated to the treatment of autoimmune diseases, announced today the receipt of a $2 million grant from the National Institutes of Health (NIH) to advance novel therapies for autoimmune diseases.

22-Aug-2024 11:05 AM EDT
New Study: Drug May Stop Migraines Before Headache Starts
American Academy of Neurology (AAN)

When taken at the first signs of a migraine, before headache pain begins, a drug called ubrogepant may be effective in helping people with migraine go about their daily lives with little or no symptoms, according to a new study published in the August 28, 2024, online issue of Neurology®, the medical journal of the American Academy of Neurology.

Released: 27-Aug-2024 7:05 AM EDT
A human-centered AI tool to improve sepsis management
Ohio State University

A proposed artificial intelligence tool to support clinician decision-making about hospital patients at risk for sepsis has an unusual feature: accounting for its lack of certainty and suggesting what demographic data, vital signs and lab test results it needs to improve its predictive performance.

Newswise: New technique paves the way for efficient Vitamin D3 production
Released: 27-Aug-2024 7:05 AM EDT
New technique paves the way for efficient Vitamin D3 production
Chinese Academy of Sciences

Scientists have developed a new method for crafting intricate microfluidic channels in glass using intense laser pulses. These tiny channels offer exceptional clarity for ultraviolet (UV) light, making them ideal for continuous-flow photochemical reactions like synthesising vitamin D3. The technique paves the way for miniaturized, efficient chemical production methods with promising applications in medicine, materials science, and beyond.

Newswise: Study finds nearly half of U.S. counties have at least one ‘pharmacy desert’
Released: 23-Aug-2024 2:05 PM EDT
Study finds nearly half of U.S. counties have at least one ‘pharmacy desert’
Ohio State University Wexner Medical Center

Nearly half of counties in the United States have at least one ‘pharmacy desert’ where there is no retail pharmacy within 10 miles, according to a new study published by researchers at The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Research Institute (OSUCCC – James).

Released: 22-Aug-2024 7:05 AM EDT
First Patient Dosed in Phase 2 Clinical Study of Palatin's Bremelanotide Co-Administered with Tirzepatide (GLP-1) for the Treatment of Obesity
Palatin Technologies, Inc.

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that patient dosing has started for the clinical study entitled: BMT-801: A Phase II, Randomized, Double-Blind, Placebo-Controlled, Clinical Study Investigating the Safety, Tolerability, and Effectiveness of the Co-Administration of Bremelanotide with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity (ClinicalTrials.gov Identifier: NCT06565611).

Newswise: Consensus recommendations for epilepsy with eyelid myoclonia (Jeavons syndrome): Dr. Kelsey Smith
Released: 21-Aug-2024 1:05 PM EDT
Consensus recommendations for epilepsy with eyelid myoclonia (Jeavons syndrome): Dr. Kelsey Smith
International League Against Epilepsy

A recent publication outlines consensus recommendations on several aspects of managing epilepsy with eyelid myoclonia, also known as Jeavons syndrome. What are the most effective first-line medications? Are there non-pharmacologic treatment options? Can people with this type of epilepsy drive safely? Dr. Alina Ivaniuk talks to the paper’s first author, Dr. Kelsey Smith.

Newswise:Video Embedded deadly-sea-snail-toxin-could-be-key-to-making-better-medicines
VIDEO
15-Aug-2024 5:00 AM EDT
Deadly Sea Snail Toxin Could be Key to Making Better Medicines
University of Utah Health

Scientists are finding clues for how to treat diabetes and hormone disorders in an unexpected place: a toxin from one of the most venomous animals on the planet.



close
3.50442